Millipore Sigma Vibrant Logo

481981 Nifedipine - CAS 21829-25-4 - Calbiochem

Relatively selective blocker of L-type Ca2+ channels.

Nifedipine - CAS 21829-25-4 - Calbiochem : FDS (Fiches de données de sécurité), certificats d’analyse (CoA) et de qualité (CoQ), dossiers, brochures et autres documents disponibles.

Synonymes: L-Type Calcium Channel Blocker III

Primary Target: L-type Ca2+ channels
View Products on Sigmaaldrich.com
481981
Voir les Prix & la Disponibilité

Aperçu

Replacement Information

Tableau de caractéristiques principal

CAS #Empirical Formula
21829-25-4C₁₇H₁₈N₂O₆

Prix & Disponibilité

Référence DisponibilitéConditionnement Qté Prix Quantité
481981-250MG
Récupération des données relatives à la disponibilité...
—
Disponibilité limitée Disponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service

      		 Ampoule plast. 250 mg
      Prix en cours de récupération
      Le prix n'a pas pu être récupéré
      La quantité minimale doit être un multiple de
      Maximum Quantity is
      À la validation de la commande Plus d'informations
      Vous avez sauvegardé ()
       
      —
      Demander le prix
      		 —
      Description
      OverviewRelatively selective blocker of L-type Ca2+ channels. One of the most extensively studied blockers of 1,4-dihydropyridine-type Ca2+ channels, and a pharmacologically-useful vasodilator. Induces apoptosis in human glioblastoma cells.
      Catalogue Number481981
      Brand Family Calbiochem®
      SynonymsL-Type Calcium Channel Blocker III
      References
      ReferencesReid, K., et al. 1997. J. Pharmacol. Exp. Ther. 283, 993.
      Kondo, S., et al. 1995. J. Neurosurg. 82, 469.
      Antkiewicz-Michaluk, L., et al. 1994. Eur. J. Pharmacol. 254, 9.
      Calabresi, P., et al. 1994. J. Neurosci. 14, 4871.
      Akman, M.S., et al. 1993. Endocrinology 132, 1286.
      Cirillo, M., et al. 1993. Circ. Res. 72, 847.
      Young, R.J., et al. 1993. Biochim. Biophys. Acta 1146, 81.
      Janis, R., et al. 1987. Adv. Drug Res. 16, 311.
      Product Information
      CAS number21829-25-4
      ATP CompetitiveN
      FormYellow solid
      Hill FormulaC₁₇H₁₈N₂O₆
      Chemical formulaC₁₇H₁₈N₂O₆
      ReversibleN
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetL-type Ca2+ channels
      Purity≥98% by UV
      Physicochemical Information
      Cell permeableN
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      RTECSUS7975000
      Safety Information
      R PhraseR: 22

      Harmful if swallowed.
      S PhraseS: 36-26

      Wear suitable protective clothing.
      In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Harmful & Carcinogenic / Teratogenic
      Storage +15°C to +30°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, refrigerate (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Référence GTIN
      481981-250MG 04055977183443

      Documentation

      Nifedipine - CAS 21829-25-4 - Calbiochem FDS

      Titre

      Fiche de données de sécurité des matériaux (FDS) 

      Nifedipine - CAS 21829-25-4 - Calbiochem Certificats d'analyse

      TitreNuméro de lot
      481981

      Références bibliographiques

      Aperçu de la référence bibliographique
      Reid, K., et al. 1997. J. Pharmacol. Exp. Ther. 283, 993.
      Kondo, S., et al. 1995. J. Neurosurg. 82, 469.
      Antkiewicz-Michaluk, L., et al. 1994. Eur. J. Pharmacol. 254, 9.
      Calabresi, P., et al. 1994. J. Neurosci. 14, 4871.
      Akman, M.S., et al. 1993. Endocrinology 132, 1286.
      Cirillo, M., et al. 1993. Circ. Res. 72, 847.
      Young, R.J., et al. 1993. Biochim. Biophys. Acta 1146, 81.
      Janis, R., et al. 1987. Adv. Drug Res. 16, 311.
      Fiche technique

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision15-May-2008 RFH
      SynonymsL-Type Calcium Channel Blocker III
      DescriptionRelatively selective blocker of L-type Ca2+ channels. One of the most extensively studied Ca2+ channel blockers of 1,4-dihydropyridine-type and a pharmacologically useful vasodilator. Induces apoptosis in human glioblastoma cells.
      FormYellow solid
      CAS number21829-25-4
      RTECSUS7975000
      Chemical formulaC₁₇H₁₈N₂O₆
      Structure formulaStructure formula
      Purity≥98% by UV
      SolubilityDMSO or Ethanol
      Storage Protect from light
      +15°C to +30°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, refrigerate (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Harmful & Carcinogenic / Teratogenic
      Merck USA index14, 6528
      ReferencesReid, K., et al. 1997. J. Pharmacol. Exp. Ther. 283, 993.
      Kondo, S., et al. 1995. J. Neurosurg. 82, 469.
      Antkiewicz-Michaluk, L., et al. 1994. Eur. J. Pharmacol. 254, 9.
      Calabresi, P., et al. 1994. J. Neurosci. 14, 4871.
      Akman, M.S., et al. 1993. Endocrinology 132, 1286.
      Cirillo, M., et al. 1993. Circ. Res. 72, 847.
      Young, R.J., et al. 1993. Biochim. Biophys. Acta 1146, 81.
      Janis, R., et al. 1987. Adv. Drug Res. 16, 311.